Scholarlink

Purpose <p>This subgroup analysis of the PERSEUS study aimed to describe the effectiveness of cefiderocol treatment in the early access programme in Spain in patients infected by <i>Stenotrophomonas maltophilia</i>, <i>Burkholderia cepacia</i> complex (Bcc) or <i>Achromobacter</i> species.</p> Methods <p>In the retrospective, observational, multicentre PERSEUS study in Spain, the effectiveness and safety of cefiderocol treatment administered for at least 72&#xa0;h up to 28 days in patients infected by Gram-negative bacteria, except <i>Acinetobacter</i> spp., in the early access programme was investigated. Patient demographics and baseline clinical characteristics, cefiderocol use, clinical cure at end of treatment, all-cause mortality at Day 28 were the main outcomes.</p> Results <p>A total of 20 patients had <i>S. maltophilia</i> infections, and 14 patients had other rare glucose non-fermenters (Bcc 8, <i>Achromobacter</i> spp. 5, <i>Ralstonia mannitolilytica</i> 1). The median (interquartile range [IQR]) age was 60.5 (48.0–65.5) years and 49.5 (33.0–59.0) years for patients with <i>S. maltophilia</i> and other rare non-fermenters, respectively. The majority of patients had respiratory tract infections (<i>S. maltophilia</i> 55%; other rare non-fermenters 71.4%), and median (IQR) duration of cefiderocol treatment was 10.0 (6.5–13.5) days and 8.0 (6–14) days, respectively. Clinical cure rates were 70%, 62.5% and 80.0% for patients with <i>S. maltophilia</i>, Bcc and <i>Achromobacter</i> spp., respectively. Corresponding 28-day all-cause mortality rates were 30.0%, 37.5% and 40.0%, respectively. One patient with <i>R. mannitolilytica</i> had clinical cure and survived to Day 28.</p> Conclusions <p>Cefiderocol is an important addition to the limited treatment options for patients infected by these rare glucose non-fermenting Gram-negative bacteria.</p> Trial registration <p>ClinicalTrials.gov: NCT05789199 (Registration date: 16 February 2023).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月24日

查看全文
  • Julian Torre-Cisneros,
  • Ricard Ferrer,
  • Carmen De La Fuente Martos,
  • Jessica Sarda,
  • A. Javier Gonzalez Calvo,
  • Stefano Verardi,
  • Andreas Karas,
  • Alex Soriano

摘要

Purpose

This subgroup analysis of the PERSEUS study aimed to describe the effectiveness of cefiderocol treatment in the early access programme in Spain in patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex (Bcc) or Achromobacter species.

Methods

In the retrospective, observational, multicentre PERSEUS study in Spain, the effectiveness and safety of cefiderocol treatment administered for at least 72 h up to 28 days in patients infected by Gram-negative bacteria, except Acinetobacter spp., in the early access programme was investigated. Patient demographics and baseline clinical characteristics, cefiderocol use, clinical cure at end of treatment, all-cause mortality at Day 28 were the main outcomes.

Results

A total of 20 patients had S. maltophilia infections, and 14 patients had other rare glucose non-fermenters (Bcc 8, Achromobacter spp. 5, Ralstonia mannitolilytica 1). The median (interquartile range [IQR]) age was 60.5 (48.0–65.5) years and 49.5 (33.0–59.0) years for patients with S. maltophilia and other rare non-fermenters, respectively. The majority of patients had respiratory tract infections (S. maltophilia 55%; other rare non-fermenters 71.4%), and median (IQR) duration of cefiderocol treatment was 10.0 (6.5–13.5) days and 8.0 (6–14) days, respectively. Clinical cure rates were 70%, 62.5% and 80.0% for patients with S. maltophilia, Bcc and Achromobacter spp., respectively. Corresponding 28-day all-cause mortality rates were 30.0%, 37.5% and 40.0%, respectively. One patient with R. mannitolilytica had clinical cure and survived to Day 28.

Conclusions

Cefiderocol is an important addition to the limited treatment options for patients infected by these rare glucose non-fermenting Gram-negative bacteria.

Trial registration

ClinicalTrials.gov: NCT05789199 (Registration date: 16 February 2023).